The controversy surrounding the potential pick continues.
Maggie Mahar has some real concerns about Dr. Gupta’s history, including his propensity to support the products and treatments he reports on. With lobbyists having the potential to obstruct health reform every step of the way, the Surgeon General should “serve the interests of patients-ahead of the interests of those who profit from our bloated $2.3 trillion health care system.”
She points out, for instance, that Dr. Gupta dismissed the dangers of Vioxx, and defended Merck, prior to the medication being taken off the market.
Will he have the backbone to stand up against the special interests?
